|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
Our results may indicate that the SSTR5 gene is involved in the etiology of BPAD or may exist in linkage disequilibrium with a susceptibility gene close to SSTR5.
|
12192619 |
2002 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Our results may indicate that the SSTR5 gene is involved in the etiology of BPAD or may exist in linkage disequilibrium with a susceptibility gene close to SSTR5.
|
12192619 |
2002 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
These genes include GRM7, previously associated to major depression disorder and bipolar disorder, SLC6A13, in anxiety disorders, and S100B, SSTR5 and COMT in schizophrenia.
|
20398908 |
2010 |
|
Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
At 4 weeks after SE, SRIF1-family (SSTR 2A, SSTR2B, and SSTR5) immunoreactivity was increased only in neuropil.
|
18951627 |
2009 |
|
Unipolar Depression
|
0.300 |
Biomarker
|
disease |
PSYGENET |
These genes include GRM7, previously associated to major depression disorder and bipolar disorder, SLC6A13, in anxiety disorders, and S100B, SSTR5 and COMT in schizophrenia.
|
20398908 |
2010 |
|
Petit mal status
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Grand Mal Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Complex Partial Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Status Epilepticus, Subclinical
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Non-Convulsive Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Major Depressive Disorder
|
0.300 |
Biomarker
|
disease |
PSYGENET |
These genes include GRM7, previously associated to major depression disorder and bipolar disorder, SLC6A13, in anxiety disorders, and S100B, SSTR5 and COMT in schizophrenia.
|
20398908 |
2010 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Pituitary and hypothalamic somatostatin receptor subtype messenger ribonucleic acid expression in the food-deprived and diabetic rat.
|
7956902 |
1994 |
|
Acromegaly
|
0.060 |
Biomarker
|
disease |
BEFREE |
Our aim was to evaluate the value of the immunohistochemical (IHC) scores of 2 subtypes, SSTR2 and SSTR5, in predicting the short-term efficacy of SSA therapy in patients with active acromegaly.
|
28396686 |
2017 |
|
Acromegaly
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation.
|
21744088 |
2012 |
|
Acromegaly
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
To investigate in patients with active acromegaly whether response to SRL treatment correlates to PAS-LAR treatment and to what extent SSTR2 and SSTR5 expression are correlated to the response to PAS-LAR treatment.
|
30346538 |
2019 |
|
Acromegaly
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
SSTR5 is expressed predominantly in mammosomatotroph-derived tumors, suggesting that this receptor subtype may be an important determinant of GH secretion in acromegaly.
|
7521350 |
1994 |
|
Acromegaly
|
0.060 |
Biomarker
|
disease |
BEFREE |
The SSTR5 gene coding region and 2000 bp upstream region was sequenced in 48 patients with acromegaly and 96 control subjects.
|
21810856 |
2011 |
|
Acromegaly
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
These data suggest a role for SSTR5 t-461c and c1004t alleles in influencing GH and IGF-I levels in patients with acromegaly, whereas SSTR2 and SSTR5 variants seem to have a minor role in determining the responsiveness to somatostatin analogs.
|
15914528 |
2005 |
|
Growth Hormone-Secreting Pituitary Adenoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
By contrast, expression of SSTR5 was only found in sparsely but not in densely granulated somatotroph adenomas (membrane expression 29 vs 0%; cytoplasmic expression 57 vs 0%).
|
23847328 |
2013 |
|
Growth Hormone-Secreting Pituitary Adenoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical expression level of SSTR5 and the granulation pattern of 9 somatotroph adenomas were retrospectively determined to test for a correlation with the therapeutic efficacy of Pasireotide-LAR.
|
31518993 |
2019 |
|
Growth Hormone-Secreting Pituitary Adenoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
The physical proximity of the PKD1 and SSTR5 genes on chromosome 16 suggests a causal relationship between ADPKD and somatotroph adenoma.
|
21744088 |
2012 |
|
Growth Hormone-Secreting Pituitary Adenoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
SSTR2 and SSTR5 expression in somatotroph adenoma tissues was determined using immunohistochemistry.
|
27455094 |
2017 |
|
Growth Hormone-Secreting Pituitary Adenoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Somatostatin (SRIF) analogs interacting with SRIF receptor subtype (SSTR) 2 and SSTR5 are known to reduce secretion in GH-secreting pituitary adenomas.
|
12788890 |
2003 |
|
Prolactinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
RESULTS IHC of SSTR subtypes in the different cohorts showed SSTR2 staining intensity scores higher than SSTR5 in TSHoma, acromegaly and prolactinoma, whereas the expression of SSTR5 was stronger than SSTR2 in corticotropinoma and NFPA.
|
28434012 |
2017 |
|
Prolactinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The SSTR5 compound, BIM-23206, produced a dose-dependent inhibition of PRL release similar to that of cabergoline in three DA-sensitive prolactinomas.
|
18426817 |
2008 |